58th Annual Meeting and Exposition (December 3-6, 2016) Bloomberg Intelligence: ASH Planner

Start Time End Time Day Location Room Company (s) Drug (s) Presentation Abstract # Manchester Grand Grand Hall Targeting of JAK/STAT Signaling to Reverse Stroma-Induced Cytoprotection Against BCL2 Antagonist 7:45 AM 08:00AM 12/03/16 AbbVie / Roche Venclexta 32 Hyatt San Diego: D Venetoclax in Acute Myeloid Leukemia San Diego A CD47xCD19 Bispecific Antibody That Remodels the Tumor Microenvironment for Improved Killing and 7:45 AM 08:00AM 12/03/16 Room 5AB Novimmune S.A. NA 44 Convention Center: Provokes a Memory Immune Response to Cancer B Cells San Diego 7:45 AM 08:00AM 12/03/16 Room 6AB Juno JCAR014 CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia 56 Convention Center: San Diego Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical 8:15 AM 08:30AM 12/03/16 Room 6AB AbbVie / J&J Imbruvica 58 Convention Center: Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL Bristol-Myers San Diego 8:30 AM 08:45AM 12/03/16 Room 6AB Squibb / Ono / Opdivo / Imbruvica Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial 59 Convention Center: AbbVie / J&J Manchester Grand Grand Hall Romiplostim in Patients Undergoing Allogeneic Stem Cell Transplantation: Results of a Phase I/II Multicenter 8:30 AM 08:45AM 12/03/16 Amgen romiplostim 65 Hyatt San Diego: B Trial San Diego AstraZeneca / Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical 8:45 AM 09:00AM 12/03/16 Room 6AB acalabrutinib 60 Convention Center: Acerta / Merck Study Seaport Outcome of Children with Primary Immune-Deficiencies (PIDs) Enrolled in a Phase I-II Trial Based on the Manchester Grand BPX-501 8:45 AM 09:00AM 12/03/16 Ballroom Bellicum Infusion of BPX-501 Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9, iC9) 72 Hyatt San Diego: (rimiducid) EFGH after T-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (haplo-HSCT) Manchester Grand Grand Hall Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of 9:30 AM 09:45AM 12/03/16 AbbVie / Roche Venclexta 97 Hyatt San Diego: A Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models Manchester Grand Grand Hall Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, 9:45 AM 10:00AM 12/03/16 Takeda pevonedistat 98 Hyatt San Diego: A Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML) San Diego Seattle Genetics / Results of an Ongoing Phase 2 Study of with Rchp As Frontline Therapy in Patients with 9:45 AM 10:00AM 12/03/16 Room 7AB Adcetris 104 Convention Center: Takeda High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL) Manchester Grand Grand Hall glasdegib (PF- A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated 10:00 AM 10:15AM 12/03/16 Pfizer 99 Hyatt San Diego: A 0449913) Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome San Diego True North TNT009 Prevents Erythrocyte C3 Fragment Opsonization and Rescues Reticulocytes from Destruction in 10:15 AM 10:30AM 12/03/16 Room 33 TNT009 94 Convention Center: Therapeutic Patients with Cold Agglutinin Disease Manchester Grand Grand Hall Helsinn / MEI A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not 10:15 AM 10:30AM 12/03/16 pracinostat 100 Hyatt San Diego: A Pharma Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit Manchester Grand Grand Hall Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance 10:30 AM 10:45AM 12/03/16 AbbVie / Roche Venclexta 101 Hyatt San Diego: A to BCL-2 Inhibitor Venetoclax in AML San Diego Room Activated FVIII Released from FVIII/VWF Complex Facilitates Thrombus Development Under High Shear Flow 10:30 AM 10:45AM 12/03/16 Roche / Chugai ACE910 83 Convention Center: 28ABCD Condition Manchester Grand Grand Hall Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with 10:45 AM 11:00AM 12/03/16 AbbVie / Roche Venclexta 102 Hyatt San Diego: A Acute Myeloid Leukemia Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Manchester Grand Grand Hall 10:45 AM 11:00AM 12/03/16 Otsuka ASTX727 (E7727) Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes 114 Hyatt San Diego: C (MDS): Final Data of Phase 1 Study San Diego Room SCD-101: A New Anti-Sickling Drug Reduces Pain and Fatigue and Improves Red Blood Cell Shape in 12:00 PM 12:15PM 12/03/16 Invenux SCD-101 121 Convention Center: 28ABCD Peripheral Blood of Patients with Sickle Cell Disease San Diego Ballroom Halozyme / Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with 12:00 PM 12:15PM 12/03/16 Rituxan 145 Convention Center: 20CD Roche / Biogen Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group San Diego Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic 12:30 PM 12:45PM 12/03/16 Room 29 Shire BAX930 135 Convention Center: Purpura (Upshaw-Schulman Syndrome (USS)) San Diego PD-L1 Expression Identifies High Risk Diffuse Large B-Cell Lymphoma and Is Associated with Several 12:30 PM 12:45PM 12/03/16 Room 31 NA NA 153 Convention Center: Genomic Markers AbbVie / J&J / San Diego Ballroom Celgene Biogen / Imbruvica / Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from 12:45 PM 01:00PM 12/03/16 148 Convention Center: 20CD Roche / Revlimid / Rituxan the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial Halozyme 58th Annual Meeting and Exposition (December 3-6, 2016) Bloomberg Intelligence: ASH Planner

Start Time End Time Day Location Room Company (s) Drug (s) Presentation Abstract # San Diego 1:00 PM 01:15PM 12/03/16 Room 30 Portola andexanet alfa Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa 143 Convention Center: Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Combination with Azacitidine (AZA) for Primary San Diego 2:00 PM 02:15PM 12/03/16 Room 29 GlaxoSmithKline eltrombopag Treatment of Myelodysplastic Syndromes (MDS) Patients with Thrombocytopenia: Outcomes from the 163 Convention Center: Randomized, Placebo-Controlled, Phase III Support Study Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing San Diego Seattle Genetics / 2:15 PM 02:30PM 12/03/16 Room 6AB Adcetris Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza 182 Convention Center: Takeda Study San Diego Marriott Marquis San Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic 2:30 PM 02:45PM 12/03/16 Ballroom Novartis nelarabine 177 Diego Marina: Leukemia and T-Lymphoblastic Lymphoma AB San Diego Bristol-Myers A Phase 1 Study of Nivolumab in Combination with for Relapsed or Refractory Hematologic 2:30 PM 02:45 PM 12/03/16 Room 6AB Opdivo / Yervoy Convention Center: Squibb / Ono Malignancies (CheckMate 039) San Diego Specific Inhibition of AKT with ARQ 092, an Orally-Available Selective AKT Inhibitor, Attenuates Acute Vaso- 2:45 PM 03:00PM 12/03/16 Room 7AB ArQule ARQ 092 160 Convention Center: Occlusive Events in Sickle Cell Disease Gilead / Biogen / San Diego Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for 3:15 PM 03:30PM 12/03/16 Room 5AB Roche / Zydelig / Rituxan 192 Convention Center: Relapsed Chronic Lymphocytic Leukemia Halozyme San Diego SGN-CD33A Marriott Marquis San A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly 4:00 PM 04:15PM 12/03/16 Ballroom Seattle Genetics (vadastuximab 211 Diego Marina: Diagnosed Acute Myeloid Leukemia (AML) AB talirine) Marriott Marriott Marquis San Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and 4:00 PM 04:15PM 12/03/16 Grand 11- Novartis CTL119 217 Diego Marina: Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia 13 Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Manchester Grand Grand Hall Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic 4:00 PM 04:15PM 12/03/16 Celgene Revlimid 223 Hyatt San Diego: C Syndrome (MDS): Results of the E2905 Intergroup Study—an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health Seaport Manchester Grand 4:00 PM 04:15 PM 12/03/16 Ballroom Celgene Revlimid Final Analysis of Overall Survival from the First Trial 241 Hyatt San Diego: ABCD Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Manchester Grand Grand Hall Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or 4:15 PM 04:30PM 12/03/16 Celgene Revlimid 224 Hyatt San Diego: C Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10) San Diego Results of the Phase 3 Study of Lenalidomide Versus Placebo As Maintenance Therapy Following Second-Line 4:15 PM 04:30PM 12/03/16 Room 5AB Celgene Revlimid 230 Convention Center: Treatment for Patients with Chronic Lymphocytic Leukemia (the CONTINUUM Trial) Marriott Marriott Marquis San CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged 4:30 PM 04:45PM 12/03/16 Grand 11- Juno JCAR017 219 Diego Marina: Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL (PLAT-02) 13 Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Manchester Grand Grand Hall 4:30 PM 04:45PM 12/03/16 Celgene Revlimid Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating 225 Hyatt San Diego: C Agents (ESAs San Diego Marriott Marquis San Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute 4:45 PM 05:00PM 12/03/16 Ballroom NA NA 214 Diego Marina: Myeloid Leukemia AB Marriott Marriott Marquis San Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ 4:45 PM 05:00PM 12/03/16 Grand 11- Novartis CTL019 220 Diego Marina: Leukemia 13 Seaport Manchester Grand Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III 4:45 PM 05:00PM 12/03/16 Ballroom Celgene Revlimid 244 Hyatt San Diego: Myeloma XI Study ABCD 58th Annual Meeting and Exposition (December 3-6, 2016) Bloomberg Intelligence: ASH Planner

Start Time End Time Day Location Room Company (s) Drug (s) Presentation Abstract # San Diego Marriott Marquis San Stemline Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid 5:00 PM 05:15PM 12/03/16 Ballroom SL-401 215 Diego Marina: Therapeutics Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD) AB Manchester Grand Grand Hall Opsona A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk 5:00 PM 05:15PM 12/03/16 OPN-305 227 Hyatt San Diego: C Therapeutics Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy San Diego 5:15 PM 05:30PM 12/03/16 Room 33 Celgene Pomalyst Pomalidomide in Hereditary Hemorrhagic Telangiectasia: Interim Results of a Phase I Study 210 Convention Center: Marriott Health-Related Quality of Life (HRQoL) of Versus Standard of Care (SOC) Chemotherapy in Marriott Marquis San 5:15 PM 05:30PM 12/03/16 Grand 11- Amgen / Astellas Blincyto Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in 222 Diego Marina: 13 a Randomized, Open-Label Phase 3 Study (TOWER) Manchester Grand Grand Hall APG101 Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk 5:15 PM 05:30PM 12/03/16 Apogenix 228 Hyatt San Diego: C (asunercept) MDS: Results from a Phase I Study San Diego AbbVie / J&J / Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T 5:30 PM 7:30PM 12/03/16 Hall GH Imbruvica / CTL019 2159 Convention Center: Novartis Cells (CART) for B Cell Neoplasms San Diego Phase 1 Clinical Trial of Adoptive Immunotherapy Using “Off-the-Shelf” Activated Natural Killer Cells (aNK) in 5:30 PM 7:30PM 12/03/16 Hall GH NantKwest aNK 1649 Convention Center: Patients with Refractory/Relapsed Acute Myeloid Leukemia San Diego Biosimilar Rituxan A Phase III Efficacy and Safety Study of the Proposed Rituximab Biosimilar GP2013 Versus Rituximab in 5:30 PM 7:30PM 12/03/16 Hall GH Novartis 1809 Convention Center: (GP2013) Patients with Previously Untreated Advanced Follicular Lymphoma San Diego First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent 5:30 PM 7:30PM 12/03/16 Hall GH Sunesis SNS-062 2032 Convention Center: Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects San Diego CC-122 / CC-223 / A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC‑292, and 5:30 PM 7:30PM 12/03/16 Hall GH Celgene 1849 Convention Center: CC-292 Rituximab in Diffuse Large B‑Cell Lymphoma: CC-122-DLBCL-001 San Diego CC-122 Is a Cereblon Modulating Agent That Is Active in Lenalidomide-Resistant and 5:30 PM 7:30PM 12/03/16 Hall GH Celgene CC-122 1592 Convention Center: Lenalidomide/Dexamethasone-Double-Resistant Multiple Myeloma Pre-Clinical Models San Diego Interim Data from a Randomized, Placebo Controlled, Phase 1 Study of Aln-AS1, an Investigational RNAi 5:30 PM 7:30PM 12/03/16 Hall GH Alnylam ALN-AS1 2318 Convention Center: Therapeutic for the Treatment of Acute Hepatic Porphyria San Diego Update from the Hgb-205 Phase 1/2 Clinical Study of Lentiglobin Gene Therapy: Sustained Clinical Benefit in 5:30 PM 7:30PM 12/03/16 Hall GH Bluebird BB305 (lentiGlobin) 2311 Convention Center: Severe Hemoglobinopathies San Diego Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with 5:30 PM 7:30PM 12/03/16 Hall GH uniQure AMT-060 2314 Convention Center: Severe Hemophilia B Safety and Efficacy of Venetoclax and in Patients with Previously Untreated Chronic Lymphocytic San Diego 5:30 PM 7:30PM 12/03/16 Hall GH AbbVie / Roche Venclexta / Gazyva Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized 2054 Convention Center: CLL14 Trial (BO25323) Sanofi / San Diego 5:30 PM 7:30PM 12/03/16 Hall GH Immunogen / (SAR650984) / Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma 2111 Convention Center: Amgen Kyprolis Sanofi / isatuximab San Diego Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and 5:30 PM 7:30PM 12/03/16 Hall GH Immunogen / (SAR650984) / 2123 Convention Center: Dexamethasone in Relapsed and Refractory Multiple Myeloma Celgene Kyprolis San Diego Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated 5:30 PM 7:30PM 12/03/16 Hall GH Alnylam fitusiran 1397 Convention Center: Results from a Phase 1 and Phase 1/2 Extension Study in Patients with Inhibitors Marriott Marriott Marquis San Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with 5:00 PM 05:15PM 12/03/16 Grand 11- Novartis CTL019 221 Diego Marina: Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) 13 San Diego Wnt5a Induces ROR1 to Complex with HS1, Which Undergoes Tyrosine Phosphorylation and Contributes to 7:30 AM 07:45AM 12/04/16 Room 6AB NA NA 301 Convention Center: Planar-Cell-Polarity Migration in Chronic Lymphocytic Leukemia Marriott Marquis San Pacific Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves 9:45 AM 10:00AM 12/04/16 NA NA 338 Diego Marina: Ballroom Leukemia-Free Survival Manchester Grand Grand Hall Bristol-Myers A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with 9:45 AM 10:00AM 12/04/16 Opdivo / Yervoy 344 Hyatt San Diego: C Squibb / Ono Previously Treated or Untreated Myelodysplastic Syndromes (MDS) Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Marriott Marquis San Pacific 10:00 AM 10:15AM 12/04/16 NA NA Older Adults Age ≥60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality 339 Diego Marina: Ballroom of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial 58th Annual Meeting and Exposition (December 3-6, 2016) Bloomberg Intelligence: ASH Planner

Start Time End Time Day Location Room Company (s) Drug (s) Presentation Abstract # SGN-CD33A Marriott Marquis San Pacific A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for 10:15 AM 10:30AM 12/04/16 Seattle Genetics (vadastuximab 340 Diego Marina: Ballroom Patients with Acute Myeloid Leukemia (AML) talirine) Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Manchester Grand Grand Hall 10:15 AM 10:30AM 12/04/16 Otsuka guadecitabine Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or 346 Hyatt San Diego: C Chronic Myelomonocytic Leukemia (CMML) Marriott Marquis San Pacific Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) 10:30 AM 10:45AM 12/04/16 Karyopharm selinexor 341 Diego Marina: Ballroom Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML Marriott Marquis San Pacific Stemline Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic 10:45 AM 11:00AM 12/04/16 SL-401 342 Diego Marina: Ballroom Therapeutics Cell Neoplasm (BPDCN) Bristol-Myers Manchester Grand Grand Hall 12:30 PM 12:45PM 12/04/16 Squibb / Simcere Orencia Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease 387 Hyatt San Diego: C Pharmaceutical Manchester Grand Grand Hall TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity 1:00 PM 01:15PM 12/04/16 NA NA 389 Hyatt San Diego: C Conditioning in Children: First Results of a Prospective Multicenter Phase I/II Clinical Trial Manchester Grand Grand Hall Incyte / INCB039110 1:15 PM 01:30PM 12/04/16 A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD) 390 Hyatt San Diego: C AstraZeneca (itacitinib) SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and San Diego 2:00 PM 4:00PM 12/04/16 Hall AB Novartis SelG1 antibody Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related 1 Convention Center: Pain Crises San Diego Halozyme / Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with 2:00 PM 04:00 PM 12/04/16 Hall AB Gazyva / Rituxan 6 Convention Center: Roche / Biogen Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study -6 San Diego Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor 2:00 PM 4:00PM 12/04/16 Hall AB Spark / Pfizer SPK-9001 3 Convention Center: IX Activity Levels of >30% without Immunosuppression Marriott Marquis San Marriott PharmaEssentia / ropeginterferon alfa- Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to 4:30 PM 04:45PM 12/04/16 475 Diego Marina: Grand 8-9 AOP Orphan 2b Hydroxyurea in Polycythemia Vera Patients Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Manchester Grand Grand Hall 4:45 PM 05:00PM 12/04/16 NA NA Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation 506 Hyatt San Diego: C (HCT): Results from a Phase III Randomized Multi-Center Trial San Diego Halozyme / Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: 4:45 PM 05:00PM 12/04/16 Room 6B Gazyva / Rituxan 470 Convention Center: Roche / Biogen Final Results from an Open-Label, Randomized Phase 3 Study (GOYA) Manchester Grand Grand Hall Final Results of a Randomized Phase 2 Trial Evaluating Lower-Dose Versus Higher-Dose Pomalidomide as 5:00 PM 05:15PM 12/04/16 Celgene Pomalyst 507 Hyatt San Diego: C Therapy for Corticosteroid-Refractory Chronic Gvhd Marriott Marquis San Marriott Blueprint Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT 5:00 PM 05:15PM 12/04/16 Blu-285 477 Diego Marina: Grand 8-9 Medicines D816V in Advanced Systemic Mastocytosis (SM) San Diego First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in 5:00 PM 05:15PM 12/04/16 Room 6B Celgene Revlimid 471 Convention Center: Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa Manchester Grand Grand Hall Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell 5:15 PM 05:30PM 12/04/16 J&J / Takeda Velcade 508 Hyatt San Diego: C Transplantation: A Phase II Randomized Controlled Trial San Diego Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in 5:15 PM 05:30PM 12/04/16 Room 5AB AbbVie / J&J Imbruvica 234 Convention Center: Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Seaport Genmab / Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Manchester Grand Darzalex / Revlimid 5:15 PM 05:30PM 12/04/16 Ballroom Celgene / J&J / Treated with in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus 246 Hyatt San Diego: / Velcade ABCD Takeda Dexamethasone Marriott Marquis San Marriott Celgene / 5:15 PM 05:30PM 12/04/16 sotatercept Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia 478 Diego Marina: Grand 8-9 Acceleron San Diego Merck & Co. / Keytruda / in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple 5:15 PM 05:30PM 12/04/16 Hall AB 490 Convention Center: Celgene Pomalyst Myeloma (RRMM) San Diego Adoptive Transfer of Purified Donor-B-Lymphocytes after Allogeneic Stem Cell Transplantation: Results from a 5:15 PM 05:30PM 12/04/16 Room 6CF NA NA 502 Convention Center: Phase I/IIa Clinical Trial 58th Annual Meeting and Exposition (December 3-6, 2016) Bloomberg Intelligence: ASH Planner

Start Time End Time Day Location Room Company (s) Drug (s) Presentation Abstract # San Diego Halozyme / Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell 5:15 PM 05:30PM 12/04/16 Room 6B Rituxan 472 Convention Center: Roche / Biogen Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi selinexor / Revlimid San Diego Karyopharm / Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, 5:30 PM 05:45PM 12/04/16 Hall AB / Pomalyst / 653 Convention Center: Celgene / Amgen Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study Kyprolis San Diego AbbVie / J&J / Imbruvica / A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in 5:30 PM 05:45PM 12/04/16 Room 6B 473 Convention Center: Celgene Revlimid Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Seaport Manchester Grand Bortezomib Consolidation Following Autologous Transplant Equalizes the Outcome for Older Patients with Less 5:45 PM 06:00PM 12/04/16 Ballroom J&J / Takeda Velcade 516 Hyatt San Diego: Intensive Pretreatment Compared to Younger Patients with Newly Diagnosed Multiple Myeloma DE Lenalidomide Maintenance Significantly Improves Survival Figures in Patients with Relapsed Diffuse Large B- San Diego 5:45 PM 06:00PM 12/04/16 Room 6B Celgene Revlimid Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Final Results 474 Convention Center: of a Multicentre Phase II Tria San Diego A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of 6:00 PM 8:00PM 12/04/16 Hall GH Incyte / Novartis Jakafi 3110 Convention Center: Ruxolitinib for the Treatment of Myelofibrosis (MF) San Diego Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-δ,γ 6:00 PM 8:00PM 12/04/16 Hall GH Verasem / Infinity duvelisib 2979 Convention Center: Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab San Diego Genmab / J&J / Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or 6:00 PM 8:00PM 12/04/16 Hall GH Darzalex 3313 Convention Center: Halozyme Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor Halozyme / San Diego Safety of Subcutaneous Administration of Rituximab during the First-Line Treatment of Patients with Non- 6:00 PM 8:00PM 12/04/16 Hall GH Roche / Biogen / Rituxan 2971 Convention Center: Hodgkin Lymphoma: The MabRella Study Halozyme San Diego IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly 6:00 PM 8:00PM 12/04/16 Hall GH ImmunoGen IMGN632 2832 Convention Center: Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models San Diego Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute 6:00 PM 8:00PM 12/04/16 Hall GH Novartis CTL019 2801 Convention Center: Lymphoblastic Leukemia: Results of an Interim Analysis San Diego entospletinib (GS- Results of a Phase 2 Trial Evaluating Efficacy and Safety of Entospletinib (GS-9973) in Patients with Mantle Cell 6:00 PM 8:00PM 12/04/16 Hall GH Gilead Convention Center: 9973) Lymphoma San Diego entospletinib (GS- Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with 6:00 PM 8:00PM 12/04/16 Hall GH Gilead Convention Center: 9973) Chemotherapy in Patients with Acute Myeloid Leukemia San Diego entospletinib (GS- Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL 6:00 PM 8:00PM 12/04/16 Hall GH Gilead Convention Center: 9973) Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and San Diego 6:00 PM 8:00PM 12/04/16 Hall GH Kite KTE-C19 Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 2803 Convention Center: Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety San Diego Acetylon 6:00 PM 8:00PM 12/04/16 Hall GH ACY-241 and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Convention Center: Pharmaceuticals Myeloma (ACE-MM-200 Study) San Diego Celgene / Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk 6:00 PM 8:00PM 12/04/16 Hall GH luspatercept 3168 Convention Center: Acceleron Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study San Diego Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN 6:00 PM 8:00PM 12/04/16 Hall GH AbbVie / J&J Imbruvica 2980 Convention Center: Study San Diego Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated 6:00 PM 8:00PM 12/04/16 Hall GH Alnylam fitusiran 2572 Convention Center: Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors San Diego Effect of Complement Inhibition By Anti-C5 (Eculizumab) or a Small Molecule Inhibitor of Factor D (ACH-4471) 6:00 PM 8:00PM 12/04/16 Hall GH Alexion Soliris 2429 Convention Center: on Survival of Meningococci in Blood from Vaccinated Adults Immediate, Complete, and Sustained Inhibition of C5 with ALXN1210 Reduces Complement-Mediated San Diego 6:00 PM 8:00PM 12/04/16 Hall GH Alexion ALXN1210 Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Interim Analysis of a Dose-Escalation 2428 Convention Center: Study 58th Annual Meeting and Exposition (December 3-6, 2016) Bloomberg Intelligence: ASH Planner

Start Time End Time Day Location Room Company (s) Drug (s) Presentation Abstract # San Diego Global Blood 6:00 PM 8:00PM 12/04/16 Hall GH GBT440 Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor 2488 Convention Center: Therapeutics Seaport Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Manchester Grand 7:00 AM 07:15AM 12/05/16 Ballroom J&J / Takeda Velcade Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma 673 Hyatt San Diego: DE Network (EMN02/HO95 MM Trial) San Diego Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell 7:00 AM 07:15AM 12/05/16 Room 6B Merck & Co. Keytruda 619 Convention Center: Lymphoma: Results from the Ongoing Keynote-013 Trial San Diego AstraZeneca / Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical 7:15 AM 7:30AM 12/05/16 Room 5AB acalabrutinib 638 Convention Center: Acerta / Merck Study San Diego SGN-CD33A Marriott Marquis San Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid 7:15 AM 07:30AM 12/05/16 Ballroom Seattle Genetics (vadastuximab 590 Diego Marina: Leukemia (AML) AB talirine) San Diego Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor 7:15 AM 07:30AM 12/05/16 Room 6CF Juno JCAR018 650 Convention Center: (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Seaport Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Manchester Grand 7:15 AM 07:30AM 12/05/16 Ballroom Celgene / Takeda Revlimid / Ninlaro Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma 674 Hyatt San Diego: DE (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM) San Diego SGN-CD33A Marriott Marquis San Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in 7:30 AM 07:45AM 12/05/16 Ballroom Seattle Genetics (vadastuximab 591 Diego Marina: Frontline Older Patients with Acute Myeloid Leukemia (AML) AB talirine) Seaport Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Manchester Grand 7:30 AM 07:45AM 12/05/16 Ballroom Celgene / Amgen Revlimid / Kyprolis Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple 675 Hyatt San Diego: DE Myeloma (NDMM) Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival San Diego 7:30 AM 07:45AM 12/05/16 Room 6DE Roche Gazyva Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: 615 Convention Center: Updated Results of the GADOLIN Study San Diego Stemline SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates 7:45 AM 08:00AM 12/05/16 Room 24 SL-401 580 Convention Center: Therapeutics Therapeutic Benefit in PDX Model Marriott Marquis San Marriott Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity 7:45 AM 08:00AM 12/05/16 NA NA 586 Diego Marina: Grand 2-4 Management San Diego Marriott Marquis San BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial 7:45 AM 08:00AM 12/05/16 Ballroom Rigel / BerGenBio BGB324 592 Diego Marina: BGBC003 and Induces Unique Changes in Biomarker Profiles AB Seattle Genetics / polatuzumab San Diego Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin 7:45 AM 08:00AM 12/05/16 Room 6B Biogen / Roche / vedotin / Gazyva / 622 Convention Center: Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study Halozyme Rituxan Marriott Marquis San Marriott Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute 8:00 AM 08:15AM 12/05/16 NA NA 587 Diego Marina: Grand 2-4 Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study San Diego Marriott Marquis San Rigel / Daiichi Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies – 8:00 AM 08:15AM 12/05/16 Ballroom DS-3032b 593 Diego Marina: Sankyo Preliminary Results AB Manchester Grand Grand Hall Treatment of Patients with Steroid Refractory Acute Graft Vs Host Disease (SR-GvHD): A Matched Paired 8:00 AM 08:15AM 12/05/16 ADIENNE begelomab 671 Hyatt San Diego: C Analysis of Anti-CD26 (Begelomab) Compared to Other Treatment San Diego TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary 8:00 AM 08:15 AM 12/05/16 Room 5AB AbbVie / J&J Imbruvica 641 Convention Center: Results of a Multicenter Phase I/Ib Study San Diego Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin’s Lymphoma (NHL): Results from Diffuse 8:00 AM 08:15 AM 12/05/16 Room 6B MorphoSys MOR 208 623 Convention Center: Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study San Diego Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin’s Lymphoma (NHL): Results from Diffuse 8:00 AM 08:15AM 12/05/16 Room 6B MorphoSys MOR 208 623 Convention Center: Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Marriott Marquis San Marriott inotuzumab in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline 8:15 AM 08:30AM 12/05/16 Pfizer 588 Diego Marina: Grand 2-4 ozogamicin Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial 58th Annual Meeting and Exposition (December 3-6, 2016) Bloomberg Intelligence: ASH Planner

Start Time End Time Day Location Room Company (s) Drug (s) Presentation Abstract # Marriott Marquis San Marriott Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia 10:30 AM 10:45AM 12/05/16 Ariad Iclusig 757 Diego Marina: Grand 2-4 Chromosome Positive Acute Lymphoblastic Leukemia Pacific Marriott Marquis San Discontinuation of Nilotinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Deep Molecular 11:15 AM 11:30AM 12/05/16 Ballroom Novartis Tasgina 790 Diego Marina: Responses for at Least 2 Years: A Multicenter Phase 2 Stop Nilotinib (Nilst) Trial 18-19 Seaport Early Post-Transplant Epigenetic Therapy By Panobinostat and Decitabine Followed By Donor Lymphocyte Manchester Grand 11:15 AM 11:30AM 12/05/16 Ballroom Novartis Farydak Infusion (DLI): Interim Results of the HOVON-116 Phase I/II Feasibility Study in Poor-Risk AML Recipients of 832 Hyatt San Diego: DE Allogeneic Stem Cell Transplantation (alloHSCT) San Diego TET1 Promotes Leukemic Growth in T-ALL Via Maintenance of 5-Hydroxymethylation Marks and Can be 11:30 AM 11:45AM 12/05/16 Room 31 AstraZeneca Lynparza 737 Convention Center: Antagonized By the PARP Inhibitor Olaparib Pacific Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Marriott Marquis San Bristol-Myers 11:30 AM 11:45AM 12/05/16 Ballroom Sprycel Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A 791 Diego Marina: Squibb 18-19 Prospective, Multicenter Japanese Trial (D-STOP Trial) San Diego Marriott Marquis San A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia 11:45 AM 12:00PM 12/05/16 Ballroom ImmunoGen IMGN632 768 Diego Marina: (AML) Cells While Sparing Normal Bone Marrow Cells AB San Diego Ballroom IL-18 Secreting CAR T Cells Enhance Cell Persistence, Induce Prolonged B Cell Aplasia and Eradicate CD19+ 11:45 AM 12:00PM 12/05/16 Juno NA 816 Convention Center: 20A Tumor Cells without Need for Prior Conditioning Manchester Grand Grand Hall Sanofi- Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific , in Patients with CD20+ 2:45 PM 03:00PM 12/05/16 REGN 1979 979 Hyatt San Diego: B Regeneron B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy Seaport Manchester Grand Karyopharm / Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory 2:45 PM 03:00PM 12/05/16 Ballroom selinexor / Kyprolis 973 Hyatt San Diego: Amgen Multiple Myeloma (RRMM) BC ATRA, Arsenic Trioxide (ATO), and (GO) Is Safe and Highly Effective in Patients with Marriott Marquis San Marriott Pfizer / Takeda / 3:00 PM 03:15PM 12/05/16 Mylotarg Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL): Final Results of the 896 Diego Marina: Grand 5-6 UCB SWOG/Alliance/ECOG S0535 Trial A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary San Diego 3:00 PM 03:15PM 12/05/16 Room 24 Kite KTE-C19 Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From 998 Convention Center: ZUMA-1 San Diego Marriott Marquis San vosaroxin Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with 3:15 PM 03:30PM 12/05/16 Ballroom Sunesis 903 Diego Marina: (Qinprezo) Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial AB Pacific Marriott Marquis San Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular 3:15 PM 03:30PM 12/05/16 Ballroom Novartis Tasgina 939 Diego Marina: Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study 18-19 San Diego Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: 3:30 PM 03:45PM 12/05/16 Room 7AB Novartis deferasirox 850 Convention Center: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study San Diego Celgene / Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with 3:45 PM 04:00PM 12/05/16 Room 7AB luspatercept 851 Convention Center: Acceleron Beta-Thalassemia San Diego A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children 3:45 PM 04:00PM 12/05/16 Room 29 Amgen romiplostim 869 Convention Center: with Immune Thrombocytopenia (ITP) Marriott Marquis San Marriott The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased 3:45 PM 04:00PM 12/05/16 J&J / Takeda Velcade 899 Diego Marina: Grand 5-6 Toxicity without Therapeutic Benefit: A Report from the Children’s Oncology Group San Diego Marriott Marquis San CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with 3:45 PM 04:00PM 12/05/16 Ballroom Celgene CC-486 905 Diego Marina: Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies AB San Diego Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, 4:00 PM 04:15PM 12/05/16 Room 7AB Incyte / Novartis Jakafi 852 Convention Center: Multicenter, Phase 2a Truth Study Marriott Marquis San Marriott A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study 4:00 PM 04:15PM 12/05/16 NA NA 900 Diego Marina: Grand 5-6 NCI 8485 San Diego Astellas / Marriott Marquis San Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of 4:30 PM 04:45PM 12/05/16 Ballroom Kotobuki gilteritinib 1069 Diego Marina: Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) AB Pharmaceutical 58th Annual Meeting and Exposition (December 3-6, 2016) Bloomberg Intelligence: ASH Planner

Start Time End Time Day Location Room Company (s) Drug (s) Presentation Abstract # Celgene / Biogen San Diego Ballroom Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need 4:30 PM 04:45PM 12/05/16 / Roche / Revlimid / Rituxan 1099 Convention Center: 20A of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10 Halozyme San Diego Ballroom Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, 4:45 PM 05:00PM 12/05/16 Novartis CTL019 1100 Convention Center: 20A Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy San Diego Marriott Marquis San Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 4:45 PM 05:00PM 12/05/16 Ballroom Agios AG-120 1070 Diego Marina: Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1 AB Manchester Grand Grand Hall Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with 4:45 PM 05:00PM 12/05/16 NA NA 1160 Hyatt San Diego: C Relapse after Allogeneic Transplantation San Diego Genmab / J&J / Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of 5:00 PM 05:15PM 12/05/16 Hall AB Darzalex 1149 Convention Center: Halozyme Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO) San Diego Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term 5:00 PM 05:15PM 12/05/16 Room 6B Merck & Co. Keytruda 1108 Convention Center: Efficacy from the Phase 1b Keynote-013 Study

Seaport Manchester Grand Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase 5:00 PM 05:15PM 12/05/16 Ballroom Celgene Revlimid 1143 Hyatt San Diego: III Myeloma XI Study BC

San Diego Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 5:00 PM 05:15PM 12/05/16 Room 6B Merck & Co. Keytruda 1107 Convention Center: 2 Keynote-087 Study San Diego Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Marriott Marquis San AROG 5:00 PM 05:15PM 12/05/16 Ballroom crenolanib Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute 1071 Diego Marina: Pharmaceuticals AB Myeloid Leukemia (AML) San Diego Ballroom Halozyme / Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of 5:30 PM 05:45PM 12/05/16 Rituxan 1103 Convention Center: 20A Roche / Biogen the Phase 3 SABRINA Study San Diego ISIS- 5:30 PM 05:45PM 12/05/16 Room 7AB Ionis? Developing a Galnac-Conjugated TMPRSS6 Antisense Therapy for the Treatment of β-Thalassemia 1013 Convention Center: TMPRSS6LRx? San Diego Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated 5:30 PM 05:45PM 12/05/16 Room 6CF Ariad Iclusig 1061 Convention Center: with Ponatinib San Diego Marriott Marquis San A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and 5:30 PM 05:45PM 12/05/16 Ballroom Novartis IDH305 1073 Diego Marina: MDS That Harbor IDH1R132 Mutations AB San Diego Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia: Update from the Northstar Hgb-204 5:30 PM 05:45PM 12/05/16 Room 24 Bluebird BB305 (lentiGlobin) 1175 Convention Center: Phase 1/2 Clinical Study San Diego Celgene / Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in 5:30 PM 05:45PM 12/05/16 Hall AB Revlimid / Darzalex 1151 Convention Center: Genmab / J&J Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux San Diego A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or 5:45 PM 06:00PM 12/05/16 Hall AB MorphoSys MOR202 1152 Convention Center: Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma San Diego 5:45 PM 06:00PM 12/05/16 Room 24 Bluebird BB305 (lentiGlobin) Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease 1176 Convention Center: San Diego Bristol-Myers Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with 5:45 PM 06:00PM 12/05/16 Room 6B Opdivo 1110 Convention Center: Squibb / Ono Relapsed/Refractory Classical Hodgkin Lymphoma San Diego Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High 6:00 PM 08:00PM 12/05/16 Hall GH Juno JCAR017 4192 Convention Center: Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 58th Annual Meeting and Exposition (December 3-6, 2016) Bloomberg Intelligence: ASH Planner

Start Time End Time Day Location Room Company (s) Drug (s) Presentation Abstract #

San Diego The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI 6:00 PM 8:00PM 12/05/16 Hall GH Celgene Revlimid 4412 Convention Center: Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM)

Genmab / J&J / San Diego Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory 6:00 PM 8:00PM 12/05/16 Hall GH Halozyme / Darzalex / Pomalyst 4516 Convention Center: Multiple Myeloma: A Real Life Retrospective Evaluation Celgene San Diego CD19 Target Activated Natural Killer (CD19.TaNK) Cellular Therapy: A Novel immunotherapeutic Approach to 6:00 PM 8:00PM 12/05/16 Hall GH NantKwest aNK 4174 Convention Center: the Treatment of Non-Hodgkin Lymphoma (NHL) San Diego Bleeding Events and Safety Outcomes in Patients with Hemophilia a with Inhibitors: A Prospective, Multicenter, 6:00 PM 8:00PM 12/05/16 Hall GH Roche / Chugai ACE910 3800 Convention Center: Non-Interventional Study San Diego A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse 6:00 PM 8:00PM 12/05/16 Hall GH Celgene / Roche CC-122 / Gazyva 4199 Convention Center: Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for San Diego 6:00 PM 8:00PM 12/05/16 Hall GH Alnylam ALN-CC5 Treatment of PNH and Complement-Mediated Diseases: Preliminary Phase 1/2 Study Results in Patients with 3891 Convention Center: PNH Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with San Diego 6:00 PM 8:00PM 12/05/16 Hall GH MorphoSys MOR 208 Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter’s Transformation or Ibrutinib for 4386 Convention Center: Patients with Ibrutinib-Resistant Clones San Diego Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and 6:30 PM 06:45PM 12/05/16 Room 30 Kiadis Pharma ATIR101 1226 Convention Center: Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL San Diego Production of Anti-CD19 CAR T Cells for ZUMA-3 and -4: Phase 1/2 Multicenter Studies Evaluating KTE-C19 in 6:45 PM 07:00PM 12/05/16 Room 30 Kite KTE-C19 1227 Convention Center: Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL)

AbbVie / Bristol- San Diego Ballroom Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results 7:15 PM 7:30:00PM 12/05/16 Myers Squibb / Imbruvica / Opdivo 1217 Convention Center: 20BC from the Open‑Label, Multicenter, Phase 2 DAWN Study Ono

Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance San Diego 7:30 AM 9:00 AM 12/06/16 Hall AB Celgene Revlimid (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): LBA-1 Convention Center: Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial) San Diego Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure 7:30 AM 9:00 AM 12/06/16 Hall AB AbbVie / J&J Imbruvica LBA-3 Convention Center: of Corticosteroids San Diego Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including 7:30 AM 9:00 AM 12/06/16 Hall AB CTI BioPharma pacritinib LBA-5 Convention Center: Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl San Diego Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell 7:30 AM 9:00 AM 12/06/16 Hall AB Kite KTE-C19 LBA-6 Convention Center: Lymphoma (DLBCL): Results from the Pivotal Phase 2 ZUMA-1

Note: Please double check times, dates, and rooms with the planner published at the conference in case of changes